Sara Pilotto
Sara Pilotto
Medical Oncology, University of Verona
Verified email at
Cited by
Cited by
Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials iná…
L Carbognin, S Pilotto, M Milella, V Vaccaro, M Brunelli, A Cali˛, ...
PloS one 10 (6), e0130142, 2015
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role forá…
M Simbolo, A Mafficini, KO Sikora, M Fassan, S Barbi, V Corbo, ...
The Journal of pathology 241 (4), 488-500, 2017
Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC
I Chaib, N Karachaliou, S Pilotto, J Codony Servat, X Cai, X Li, ...
JNCI: Journal of the National Cancer Institute 109 (9), djx014, 2017
Role of mTOR signaling in tumor microenvironment: an overview
F Conciatori, C Bazzichetto, I Falcone, S Pilotto, E Bria, F Cognetti, ...
International Journal of Molecular Sciences 19 (8), 2453, 2018
mTOR cross-talk in cancer and potential for combination therapy
F Conciatori, L Ciuffreda, C Bazzichetto, I Falcone, S Pilotto, E Bria, ...
Cancers 10 (1), 23, 2018
Physical activity and exercise in lung cancer care: will promises be fulfilled?
A Avancini, G Sartori, A Gkountakos, M Casali, I Trestini, D Tregnago, ...
The oncologist 25 (3), e555-e569, 2020
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
F Facchinetti, G Mazzaschi, F Barbieri, F Passiglia, F Mazzoni, R Berardi, ...
European Journal of Cancer 130, 155-167, 2020
Cellular and molecular biology of small cell lung cancer: an overview
N Karachaliou, S Pilotto, C Lazzari, E Bria, F de Marinis, R Rosell
Translational lung cancer research 5 (1), 2, 2016
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations
M Simbolo, S Barbi, M Fassan, A Mafficini, G Ali, C Vicentini, N Sperandio, ...
Journal of Thoracic Oncology 14 (9), 1651-1661, 2019
PTEN in lung cancer: dealing with the problem, building on new knowledge and turning the game around
A Gkountakos, G Sartori, I Falcone, G Piro, L Ciuffreda, C Carbone, ...
Cancers 11 (8), 1141, 2019
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers
M Fassan, M Simbolo, E Bria, A Mafficini, S Pilotto, P Capelli, ...
Gastric cancer 17, 442-449, 2014
Do immune checkpoint inhibitors need new studies methodology?
R Ferrara, S Pilotto, M Caccese, G Grizzi, I Sperduti, D Giannarelli, ...
Journal of thoracic disease 10 (Suppl 13), S1564, 2018
Oncogene-addicted non-small-cell lung cancer: Treatment opportunities and future perspectives
MG Ferrara, V Di Noia, E D’Argento, E Vita, P Damiano, A Cannella, ...
Cancers 12 (5), 1196, 2020
ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung
A Cali˛, A Nottegar, E Gilioli, E Bria, S Pilotto, U Peretti, S Kinspergher, ...
Journal of Thoracic Oncology 9 (5), 729-732, 2014
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm
G Pelosi, F Bianchi, E Dama, M Simbolo, A Mafficini, A Sonzogni, S Pilotto, ...
Virchows Archiv 472, 567-577, 2018
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
N Karachaliou, J Codony-Servat, C Teixidˇ, S Pilotto, A Drozdowskyj, ...
Scientific reports 5 (1), 17499, 2015
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer
F Loupakis, R Moretto, G Aprile, M Muntoni, C Cremolini, D Iacono, ...
British journal of cancer 114 (1), 30-36, 2016
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
E Bria, S Pilotto, E Amato, M Fassan, S Novello, U Peretti, T VavalÓ, ...
Oncotarget 6 (14), 12783, 2015
ROS1-rearranged non–small-cell lung cancer is associated with a high rate of venous thromboembolism: analysis from a phase II, prospective, multicenter, two-arms trial (METROS)
R Chiari, B Ricciuti, L Landi, AM Morelli, A Delmonte, G Spitaleri, ...
Clinical Lung Cancer 21 (1), 15-20, 2020
Predictive and prognostic role of tumor-infiltrating lymphocytes for early breast cancer according to disease subtypes: sensitivity analysis of randomized trials in adjuvantá…
L Carbognin, S Pilotto, R Nortilli, M Brunelli, A Nottegar, I Sperduti, ...
The oncologist 21 (3), 283-291, 2016
The system can't perform the operation now. Try again later.
Articles 1–20